Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously progressed on at least one prior androgen pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzni w wieku co najmniej 18 lat
- •Potwierdzony histologicznie rak gruczołu krokowego, który się rozprzestrzenia pomimo leczenia hormonalnego
- •Bardzo niski poziom testosteronu we krwi (poniżej 50 ng/dL)
- •Co najmniej jeden widoczny guz PSMA w badaniu PET wykonanym przy przyjęciu
- •Wcześniejsze niepowodzenie leczenia co najmniej jednym lekiem hormonalnym (abiraterone, enzalutamide, apalutamide lub darolutamide)
- •Poboczne skutki poprzedniego leczenia onkologicznego ustąpiły do minimum
- •Wystarczająco dobra funkcja narządów wewnętrznych (wątroba, nerki, szpik kostny)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 10, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
University of California, San Francisco
San Francisco, United States
Trial contact
UCSF Genitourinary Medical Oncology Recruitment
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.